<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504229</url>
  </required_header>
  <id_info>
    <org_study_id>GC-A-004</org_study_id>
    <nct_id>NCT02504229</nct_id>
  </id_info>
  <brief_title>DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Biohealthcare Biotechnology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Biohealthcare Biotechnology Co.,Ltd</source>
  <brief_summary>
    <textblock>
      This study evaluates the therapeutic effects of autologous dendritic cells co-cultured with
      cytokine-induced killer cells (DC-CIK) combined with S-1 ((Tegafur, Gimeracil, and Oteracil
      Potassium) and oxaliplatin adjuvant chemotherapy in locally advanced unresectable or
      metastaticgastric cancer. Half of participants will receive DC-CIK combined with S-1 and
      oxaliplatin adjuvant chemotherapy,while the other half will receive S-1 and oxaliplatin
      adjuvant chemotherapy served as controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy+DC-CIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined treatment group:mononuclear cells were obtained aseptically with blood cell separator composition spheresis 1 day before SOX program chemotherapy, cultured DC-CIK cells. SOX program was acted on Day 2. Cells were cultured 14d,2 times back to the patient.A 21d was a cycle, then evaluated the therapeutic effect after two cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy: two groups were treated with SOX program,specific drugs:Venoclysis of oxaliplatin 130mg/㎡;Day 1; Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/㎡/d,two oral/d;Day 1 to 12; 21d as one cycle of treatment, evaluated the therapeutic effect after two cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous dendritic cells co-cultured with cytokine-induced killer cells</intervention_name>
    <arm_group_label>Chemotherapy+DC-CIK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gimeracil and Oteracil Porassium Capsules</intervention_name>
    <arm_group_label>Chemotherapy+DC-CIK</arm_group_label>
    <arm_group_label>Chemotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Chemotherapy+DC-CIK</arm_group_label>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age&gt;18y;

          2. ECOG physical status 0-1;

          3. The histologic diagnosis of stomach/gastroesophageal junction adenocarcinoma;

          4. According to the RECIST 1.1 standard with measurable or evaluable lesion;

          5. Accept swallow oral drug;

          6. WBC≧4.0×10^9/L;ALC≧0.8×10^9/L;ANC≧1.5×10^9/L;PLT≧100×10^9/L;ALT,AST≦2.5 times of the
             normal limit;ALP≦2.5 times of the normal limit;TBIL﹤1.5 times of the normal
             limit;SCr﹤1 times of the normal limit;ALB≧30g/L;

          7. The expected survival time of more than 3 months;

          8. good compliance;

          9. Provide written informed consent.

        Exclusion Criteria:

          1. Vital organs (heart,liver,kidney) function is serious dysfunction;

          2. Patients received organ transplantation;

          3. Patients with other malignant tumors or have occurred brain metastasis;

          4. Patients with history of autoimmune disease;

          5. Patients in pregnancy or breast-feeding period(women of child-bearing age need to
             check pregnancy test);

          6. Patients with acute infection disease or in chronic active stage;

          7. Patients with clear history of drug allergy or belong to allergic constitution;

          8. Patients received chemotherapy,radiation therapy, immunosuppressive drugs
             (cyclosporine A,etc.) or other immune treatment in 4 weeks;

          9. Patients received other clinical trials in 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jinwan Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences Tumor Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>lin yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences Tumor Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingwei liu, PhD</last_name>
    <phone>13241238766</phone>
    <email>ljwgirl361@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tsai Ting Huang</last_name>
    <phone>18610571563</phone>
    <email>huangct@biohealthcare.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Tumor Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jinwan Wang</last_name>
      <email>lyang69@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>lin Yang</last_name>
      <email>lyang69@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>jinwan Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>lin Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

